Review ALCMI's Past Clinical Trials

Our past clinical trials have led to new understandings of oncogene drivers and germline mutations, how lung cancer impacts younger patients, identification of genomic biomarkers, and a deeper understanding of resistance mechanisms that can inhibit treatments. Our studies have also led to numerous publications in the world’s most prestigious peer-reviewed oncology journals.

Here are our past trials.

BEACON-LUNG Study

Study to identify patients who may benefit from a triplet treatment regimen
CASTLE Study

Prospective collection of Stage 4 specimens from lung cancer patients
EGFR INHERIT Study

Investigating hereditary risk for germline EGFR mutations
EGFR PDX Study

Creating mouse models from patient specimens to support research efforts
GoYLC Study

Comprehensive genomic analysis of young lung cancer patients
LIBERTI Study

Liquid biopsy study for early-stage resected NSCLC patients
ROS1 Cell Line Study

Creating cell lines from patient specimens to support research efforts
ROS1 PDX Study

Creating mouse models from patient specimens to support research efforts
SPACEWALK Study

Study outcomes of patients with ALK+ TKI Drug Resistance

Past Studies

Clinical Trial Archive

Our Impact